US Stock MarketDetailed Quotes

APLS Apellis Pharmaceuticals

Watchlist
  • 32.190
  • -0.490-1.50%
Trading Dec 30 14:58 ET
4.00BMarket Cap-15.86P/E (TTM)

Apellis Pharmaceuticals Key Stats

Apellis Pharmaceuticals Q3 2024 Earnings Date

Currency:USDNov 5, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
199.82M
196.83M
-2.99M
Miss Est.
+81.00%
+78.29%
-1.50%
EPS
-0.31
-0.46
-0.15
Miss Est.
+73.23%
+60.68%
-46.87%
Buy

Dec 30, 2024

Apellis Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 10 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 193.749M--
--2024/Q4-- / 193.144M--
Nov 5, 20242024/Q3196.830M / 199.824M--
Aug 1, 20242024/Q2199.685M / 191.306M--
May 7, 20242024/Q1172.325M / 164.259M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 193.749M--
--2024/Q4-- / 193.144M--
Nov 5, 20242024/Q3196.830M / 199.824M--
Aug 1, 20242024/Q2199.685M / 191.306M--
May 7, 20242024/Q1172.325M / 164.259M--

Unlock Free Earnings Estimates

Apellis Pharmaceuticals Earnings Reports

Read more

Trending US Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Dec 30, 2024

Buy

  • Buy

    68.42%
  • Hold

    31.58%
  • Sell

    0.00%

Price Target

No Data